-
Innovation Ranking
NewInnovation Ranking – Viatris Inc
Viatris Inc (Viatris) is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti- retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MR-107A02 in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MR-107A02 in Post-Operative Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MR-107A02 in Post-Operative Pain Drug Details: MR-107A-02 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norelgestromin in Female Contraception
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norelgestromin in Female Contraception report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Norelgestromin in Female Contraception Drug Details: Norelgestromin is under development as a...
-
Thematic Analysis
NewPharma M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Pharma Sector
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glaucoma Clinical Trial Report Overview A total of 1,696 glaucoma clinical trials were conducted as of January 2024. The glaucoma clinical trial report provides a comprehensive understanding of the glaucoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe · North America · ...
-
Thematic Analysis
Global M&A Deals in 2023 – Top Themes by Sector – Thematic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in 2023 across all sectors including automotive, basic material, business and consumer services, consumer, energy, financial, healthcare, industrials, real estate, technology, media & telecoms, transportation, infrastructure, and logistics.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Metastatic Ovarian Cancer Drug Details: MHB-088C is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Phentolamine Mesylate in Presbyopia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Phentolamine Mesylate in Presbyopia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Phentolamine Mesylate in Presbyopia Drug Details: Phentolamine mesylate (Ryzumvi) is an antihypertensive...
-
Product Insights
IgA Nephropathy (Berger’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘IgA Nephropathy (Berger's Disease) - Drugs In Development, 2023’, provides an overview of the IgA Nephropathy (Berger's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for IgA Nephropathy (Berger's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Female Contraception – Drugs In Development, 2023
Global Markets Direct’s, ‘Female Contraception - Drugs In Development, 2023’, provides an overview of the Female Contraception pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...